Overview
Brukinsa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Waldenström’s macroglobulinemia (WM); mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer; marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment; and follicular lymphoma (FL), in combination with the medicine obinutuzumab, when the disease has come back or did not respond to treatment and who have received at least two prior treatments. Brukinsa is also referred to by its drug name, zanubrutinib.

Brukinsa is a member of a class of drugs called kinase inhibitors. Brukinsa is believed to work by inhibiting a protein called Bruton’s tyrosine kinase in cancer cells, which helps stop the cells from growing and spreading. 

How do I take it?
Prescribing information states that Brukinsa should be taken once or twice daily. Brukinsa comes in the form of a tablet. Always take as prescribed by your doctor.

Side effects
The FDA-approved label for Brukinsa lists common side effects including decreased white blood cells, decreased platelet count, anemia (decreased red blood cell count), muscle and bone pain, and upper respiratory infection.

Rare but serious side effects listed for Brukinsa include low blood cell counts, bleeding problems, infections, a risk of other cancers, fetal harm for pregnant people, and heart rhythm problems.

For more details about this treatment, visit:

Brukinsa — BeOne Medicines

Label: Brukinsa — DailyMed